anti-pvrig monoclonal antibody com701
Generic: Anti-PVRIG Monoclonal Antibody COM701
anti-pvrig monoclonal antibody com701: 1 clinical trial tracked.
anti-pvrig monoclonal antibody com701 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-pvrig monoclonal antibody com701, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
Primary endpoint: To evaluate the effect of COM701 as a single agent on progression free survival when administered as a maintenance regimen in participants with relapsed PSOC
InterventionalRandomizedtriple60 targetStarted 2025-07Completion 2027-0328 sites · France, Israel, United StatesCompugen Ltd